Effect of rosiglitazone versus insulin on the pancreatic β-cell function of subjects with type 2 diabetes

Diabetes Care

Volumn 27, Issue 11, 2004, Pages 2585-2589

  Ovalle, Fernando ^a   Bell, David S H ^a,b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE; GLUCOSE BLOOD LEVEL; HUMAN; INDX1 GENE; INNER CELL MASS; INSULIN RESPONSE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS BIOPSY; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MIDDLE AGED; PROINSULIN; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 7444230907     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.11.2585     Document Type: Article

References (18)

1. Ovalle F, Bell DSH: Clinical evidence of thiazolidinedi one-induced improvement of pancreatic beta cell function in patients with type 2 diabetes mellitus. Diabet Obes Metab 4:56-59, 2002
2. Bell DSH, Ovalle F: Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 8:271-275, 2002
3. Porter LE, Freed MI, Jones NP, Biswas N: Rosiglitazone improves B cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes (Abstract). Diabetes 49 (Suppl. 1):A122, 2000
4. Fonseca V, Rosenstock J, Patwardhan R, Salzman A: Effects of metformin and rosiglitazone therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283:1695-1702, 2000
5. Karvestedt L, Andersson G, Efendic S, Grill V: A rapid increase in β-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment. J Intern Med 251:307-316, 2002
6. Juhl CB, Hollingdale M, Porksen N, Prange A, Lonnqvist F, Schmitz O: Influence of rosiglitazone treatment on β-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsativity. J Clin Endocrinol Metab 88:3794-3800, 2003
7. Lee Y, Hirosel T, Ohneda M, Johnson JH, McGarry JD, Unger RH: Beta cell lipotoxicity of non-insulin dependent diabetes mellitus of obese rats: impairment in adipocyte-beta cell relationships. Proc Natl Acad Sci U S A 91:10878-10882, 1994
8. Shimabukura M, Koyama K, Chen G, Wang M-Y, Trieu F, Lee Y, Newgard CB, Unger RH: Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A 94:4637-4641, 1997
9. Winzell MS, Sversson H, Enerback S, Ravnskjaer K, Mandrup S, Esser V, Arner P, Alves-Guerra M-C, Miroux B, Sundler F, Ahren B, Holm C: Pancreatic β-cell lipotoxicity induced by overexpression of hormone sensitive lipase. Diabetes 52: 2057-2065, 2003
10. Shimabukuro M, Ohneda M, Lee Y, Unger RH: Role of nitric oxide in obesity-induced beta cell disease. J Clin Invest 100: 290-295, 1991
11. 2, glucokinase insulin and somatostatin levels. J Biol Chem 272:30261-30269, 1997
12. Lister CA, Moore GBT, Pierce V, Newman M, Chapman H, Smith SA: Rosiglitazone but not metformin or glibenclamide improves glycemic control and increases islet cell content (Abstract). Diabetologia 42 (Suppl. 1):A150, 1999
13. Finegood DT, McArthur MD, Kojwang D, Topp BG, Leonard T: β-Cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 50:1021-1029, 2001
14. Chop M, Grupping A, Hooren A, Bouwers L, Pipeleers-Marichal M, Pipeleers D: Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles which increases with age. Am J Pathol 156:237-244, 2000
15. Butler AE, Jurson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: β-Cell deficit and increased beta cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003
16. Wallace TM, Matthews DR: Poor glycemic control in type 2 diabetes: a conspiracy of disease, sub-optimal therapy and attitude. Q J Med 93:369-374, 2000
17. Fritsche A, Madaus A, Stefan N, Tschritter O, Maerker E, Teigeler A, Haring H, Stumvoll M: Relationships among age, proinsulin conversion, and β-cell function in nondiabetic humans. Diabetes 51 (Suppl. 1):S234-S239, 2002
18. Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K: Basal and dynamic proinsulin-insulin relationship to assess β-cell function during OGTT in metabolic disorders. Am J Physiol Endocrinol Metab 285:E155-E162, 2003